{"classes":[{"categories":[{"measurements":[{"comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 18.0 hr.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 16.6 and 30.8 hr, respectively.","groupId":"OG001","spread":"NA","value":"23.70"},{"groupId":"OG002","spread":"8.2961","value":"27.22"},{"groupId":"OG003","spread":"5.0308","value":"20.89"},{"groupId":"OG004","spread":"3.3045","value":"19.80"},{"comment":"Standard deviation was not calculated when fewer than 3 participants had reportable values. Individual values are 24.6 and 26.5 hr, respectively.","groupId":"OG005","spread":"NA","value":"25.55"},{"comment":"Summary statistics were not calculated when fewer than 3 participants had reportable values. The individual value is 26.0 hr.","groupId":"OG006","spread":"NA","value":"NA"},{"groupId":"OG007","spread":"5.1874","value":"17.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"4"}],"units":"Participants"}],"description":"Terminal plasma half-life was defined as the time measured for the plasma concentration to decrease by one half, and calculated as loge(2)/kel, where kel was the rate constant for terminal phase.","dispersionType":"Standard Deviation","groups":[{"description":"PF-06463922 10 mg was orally given once daily (QD) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG000","title":"10 mg QD (Phase 1)"},{"description":"PF-06463922 50 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG001","title":"50 mg QD (Phase 1)"},{"description":"PF-06463922 75 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG002","title":"75 mg QD (Phase 1)"},{"description":"PF-06463922 100 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG003","title":"100 mg QD (Phase 1)"},{"description":"PF-06463922 200 mg was orally given QD on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG004","title":"200 mg QD (Phase 1)"},{"description":"PF-06463922 35 mg was orally given twice daily (BID) on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG005","title":"35 mg BID (Phase 1)"},{"description":"PF-06463922 75 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG006","title":"75 mg BID (Phase 1)"},{"description":"PF-06463922 100 mg was orally given BID on Day -7 and in 21-day cycles from Cycle 1 Day 1 until progression of disease (unless clinical benefit was still achievable), unacceptable toxicity, death or consent withdrawal.","id":"OG007","title":"100 mg BID (Phase 1)"}],"paramType":"MEAN","populationDescription":"PK parameter analysis set for PF-06463922 included all enrolled participants who received at least 1 dose of PF-06463922 and had sufficient information to estimate at least one of the PK parameters of interest for PF-06463922. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9 and 24 hours post-dose on Cycle 1 Day 1 for 25 mg QD and 150 mg QD groups; pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 9, 24, 48, 72, 96 and 120 hours post-dose on Day -7 for all other groups.","title":"Terminal Half-Life of PF-06463922 Following Single Oral Doses (Phase 1)","type":"SECONDARY","unitOfMeasure":"Hours (hr)"}